Small Cap Feast

Small Cap Feast – 16 September 2019

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?


AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019

Main Market Standard

VAALCO Energy, Inc. (NYSE: EGY), an independent energy company focused on development and production assets in West Africa, today announces its formal intention to seek a Standard Listing on the Main Market of London Stock Exchange (“LSE”), to complement its existing Listing on the New York Stock Exchange., the largest Payments, Marketplace and Fintech Ecosystem in Kazakhstan with a leading market share in each of its key products and services, announces today the expected publication of a registration document that has been submitted for approval to the FCA and its potential intention, subject to market conditions, to undertake an initial public offering .

Main Market premium

Registration document approved for Helios Towers. The Group provides essential network services, flexible infrastructure solutions and reliable power supply to mobile network operators  in five African growth economies.  Revenue increased 7 per cent. year-on-year to US$191m (H1 2018: US$178m), with Adjusted EBITDA up 15 per cent. year-on-year at US$99m (H1 2018: US$86m) for the six months ended 30 June 2019.

Breakfast Buffet

Angling Direct (ANG) 64p £39m

Angling Direct plc, the largest specialist fishing tackle and equipment retailer in the UK, announced that it has opened its 30th UK store in Milton Keynes, which began trading on Saturday 14 September 2019.

The new store offers a 6,500 sq ft. display area and is located just off the A5 at Winterhill, a major retail warehouse area, south west of the City Centre, the store is also approachable from the M1 which is 3 miles to the east.

Located in a hugely popular fishing area, with a large angling community and a series of lakes and river venues, the store is the only fishing tackle “destination store” of its kind in the area. As with all Angling Direct stores, it caters for a wide range of angling disciplines, whilst also providing excellent service from local and knowledgeable staff. The new store is creating five full and three part-time positions.

Location Sciences (LSAI) 2.95p £9.95m

Location Sciences, the leading mobile location data and intelligence expert, announces a new 12-month contract with Vicinity Media, Africa’s first premium location-based ad network. The partnership will see Vicinity run verification on all its location impressions.

Vicinity Media initially implemented Verify, Location Sciences’ proprietary location verification platform, to carry out an independent audit of its location data. An analysis of over 20 campaigns between March and July 2019 revealed Vicinity Media’s clients – including Nando’s – are benefitting from near perfect scores on quality and accuracy.

To maintain this standard and provide full transparency to brands over the use of location data in their targeted advertising campaigns, Verify will now be “always-on” for Vicinity Media’s clients.

Ovoca Bio (OVB) 12p £10m

Ovoca Bio, a biopharmaceutical company focused on identifying and developing novel therapeutics targeting the large unmet needs in the treatment of female sexual dysfunction, announced its interim financial statements and report covering the six-months ending 30 June 2019. Highlights

Completion of a Phase 3 study in Russia of drug candidate BP-101 in the treatment of female sexual dysfunction, showing statistically significant improvement in primary and key secondary endpoints;

Acquisition of an additional interest in IVIX LLC (“IVIX”), increasing Ovoca’s overall holding in IVIX to 59.9%;

Cash and liquid investments at fair value of €16.5m ($19.7m) as at 30 June 2019;

Total comprehensive income for the first six-months of 2019 of €2.2m ($2.3m); and

During the period, the Company disposed of a portion of its investment portfolio. The net proceeds from the sales amounted to approximately €3.0m ($3.4m).

Adamas Fin Asia (ADAM) 30p £26.34m

Adamas Finance Asia Limited, the London quoted pan-Asian diversified investment vehicle, provided an update on its investment in Future Metal, which was previously known as Hong Kong Mining Holdings. The Company holds an 85% shareholding in Future Metal, representing ADAM’s largest investment by value in the portfolio.

The Company reported continued progress at Future Metal, which remains on track to restart production in 2019. Harmony Capital, the Investment Manager of ADAM, was instrumental in appointing a new manager and an experienced team in May 2018 following which various permits and licences have been applied for and awarded to Future Metal to enable production to restart, as confirmed by the Company on 4 September 2019.

Oilex Ltd (OEX) 0.2p £5m

The Board of Oilex announced that it has entered into an exclusivity agreement with Koru Energy a subsidiary of Koru Energy Limited, for a potential acquisition of up to a 50% relevant interest in the Knox and Lowry, and Whitbeck gas discoveries  in the East Irish Sea, offshore the United Kingdom.  

The KLW Gas Discoveries are a series of shallow water gas accumulations that were discovered between 1992 and 2009  by the then operators and successfully drill-stem tested confirming discovered volumes that the Company and Koru would seek to bring into production, should the acquisition complete. The KLW Gas Discoveries are ideally located very close to a subsea tie-back pipeline which delivers gas to the nearby and recently refurbished North Morecambe Gas Production Platform and Terminal.

Omega Diagnostics Gp (ODX) 11.75p £15.33m

Omega, the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that, following the conclusion of a quality risk assessment review by the Expert Review Panel for Diagnostics (‘ERPD’), The Global Fund has informed the Company that its VISITECT® CD4 Advanced Disease test will be included in The Global Fund procurement list. This means that VISITECT® CD4 Advanced Disease tests may be procured by organisations with access to The Global Fund or UNITAID funds, following a review of procurement requests and the issue of a No-objection letter from the Global Fund.

M. P. Evans Group (MPE) 642p £367m

M.P. Evans Group PLC, a producer of Indonesian palm oil, announces its unaudited interim results for the six months ended 30 June 2019.


6% increase in crop in first half

95,000 tonnes of CPO produced: up 3% on 2018

Increased oil-extraction rate to 23.6%

20% fall in average price of CPO to US$528 per tonne

Cost per tonne of palm product up US$35 to US$385 per tonne

Operating profit US$1.0m (2018 US$10.7m)

Interim dividend maintained at 5.00 pence per share

MTI Wireless Edge (MWE) 31p £25.88m

MTI Wireless Edge  the technology group, focused on comprehensive communication and radio frequency solutions across multiple sectors, announced that MTI Engineering Ltd, the Group’s expert consulting and representation division, has signed an agreement which includes an initial order valued at approximately US$1m, for the supply of Hi-Power Microwave Terminations to an Israeli customer over the next 16 months.       

MTIE’s General Manager, Adi Peleg, commented: “We are delighted with this agreement because it provides a lot of potential, including scope for the order size to more than double in the next two years, as our customer has designed its system around MTI’s component.

Savannah Resources (SAV) 2.05p £32m

Savannah Resources, the AIM quoted resource development company, which is focused on becoming Europe’s most significant producer of lithium spodumene concentrates from its wholly owned Mina do Barroso Project in has raised approximately £3.76m both new and existing investors at a price of 2 pence .

Rosenblatt Group PLC (RBGP) 93p £70.88m

Rosenblatt Group plc, the professional services group, has announced the acquisition of Convex Capital Limited, a specialist sell-side M&A corporate finance boutique, based in Manchester, UK.   The acquisition is in line with the Group’s M&A strategy. The total consideration for the acquisition, assuming all earn-out and deferred consideration payments are made, is £22 million

Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.